Lataa...
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). Howev...
Tallennettuna:
| Julkaisussa: | Blood |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society of Hematology
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8233666/ https://ncbi.nlm.nih.gov/pubmed/33598693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007626 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|